Open Source Pharma Foundation Competitors

Hsiri Therapeutics, a private biopharmaceutical company, is dedicated to the discovery and development of novel antibiotics to treat multi-drug resistant (MDR) infections, with a specific focus on gram-negative bacteria and mycobacterial diseases.

Since 2001, Provid has created expert medicinal chemistry solutions in drug discovery for clients in the life sciences. As the pharmaceutical industry is undergoing fundamental changes in its business models, Provid is expanding our own offering of core excellence in medicinal chemistry into areas of drug development. Over the past decade, we've helped dozens of our clients with their drug discovery needs and have gained experience in transitioning research programs into development and in managing complex projects with external resources. In addition, we built our own pipeline of proprietary projects through collaborations with academia and not-for-profit foundations and through government grants. We have matured that pipeline with substantial success, including our autoimmune and oncology projects. In the process of doing so, we have developed expertise in other technical areas of early development such as ADME, toxicology, formulation, DMPK, process development, pre-IND studies, and clinical trial design. We have invested in our capabilities to allow us to bring that same expertise directly to the benefit of our customers. We occupy a unique niche in the evolving landscape of drug discovery and development. Now, as customers continue to approach us for our craftsman-level medicinal chemistry, consulting support on due diligence projects, and offers of collaboration on early chemistry projects, we can respond not only with that level of world-class service in medicinal chemistry, but can plan and deliver directly on the downstream steps of their projects, potentially through clinical proof of concept and beyond.

A pioneer in immuno-modulation by cell specific delivery of oligonucleotide drugs to antigen presenting cells completing IND enabling studies for a groundbreaking anti-GVHD drug for hematopoietic stem cell transplantation in hematological cancers.